Second chance: cord blood transplant trial for relapsed blood cancers

NCT ID NCT06807606

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests an optimized cord blood transplant for 35 patients with high-risk blood cancers (like leukemia) who relapsed after their first stem cell transplant. Participants receive chemotherapy followed by a cord blood infusion, plus drugs to prevent rejection. The goal is to see if this approach can safely control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cord blood transplant with chemotherapy (cyclophosphamide, fludarabine, thiotepa) and immune-suppressing drugs (tacrolimus, mycophenolate mofetil)
What this could lead to: If successful, this could offer a second chance at disease control for patients with high-risk blood cancers who have relapsed after a first stem cell transplant.
What could go wrong: This is a small, early-phase trial (35 people) focused on safety, not yet proven to work. The conditioning chemotherapy and transplant carry serious risks, including infection, organ damage, and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia of ambiguous lineage acute lymphoblastic leukemia acute myeloid leukemia chronic myelomonocytic leukemia hematopoietic and lymphoid system neoplasm mixed phenotype acute leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.